EUVIMEDEUVIMED entdecken
VergleichsstudieOpen Access

Comparative Analysis of Immune-based Combination Therapy as First-line Treatment for Advanced Renal Cell Carcinoma

Yuta Mukae, Kojiro Ohba, Hiromi Nakanishi, Masaharu Oki, Ken Kawada, Tsuyoshi Matsuda, Kensuke Mitsunari, Tomohiro Matsuo, Yasushi Mochizuki, Ryoichi Imamura

In Vivo · 2026

DOI: 10.21873/invivo.14203 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift In Vivo, 2026. Verfasst von Yuta Mukae und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology and Renal Transplantation, Nagasaki University Hospital, Nagasaki, Japan. Hauptthemen laut MEDLINE: Carcinoma, Renal Cell, Kidney Neoplasms, Antineoplastic Combined Chemotherapy Protocols, Immune Checkpoint Inhibitors. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND/AIM: In advanced renal cell carcinoma (RCC), immune checkpoint inhibitor (ICI) combinations (ICI-ICI) and ICI plus tyrosine kinase inhibitor (TKI) combinations (ICI-TKI) are standard first-line therapies. However, real-world data directly comparing these approaches remain limited. This study aimed to compare treatment outcomes between ICI-ICI and ICI-TKI therapies. PATIENTS AND METHODS: We retrospectively analyzed 58 patients who received first-line ICI-ICI therapy (ipilimumab plus nivolumab) or ICI-TKI therapy (pembrolizumab plus axitinib, avelumab plus axitinib, nivolumab plus cabozantinib, or pembrolizumab plus lenvatinib) for advanced RCC at Nagasaki University Hospital (March 2018 to June 2024). Primary endpoints were progression-free survival (PFS), overall survival, and objective response rate (ORR). Safety profiles were also evaluated. RESULTS: We included 36 patients in the ICI-ICI group and 22 in the ICI-TKI group. The median follow-up was 17.5 months. The median age of patients in the ICI-TKI group was significantly older than that in the ICI-ICI group (74 vs. 66 years, p

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Renal CellKidney NeoplasmsAntineoplastic Combined Chemotherapy ProtocolsImmune Checkpoint InhibitorsHumansMaleFemaleAgedMiddle AgedRetrospective StudiesAged, 80 and overTreatment OutcomeProtein Kinase InhibitorsAdultNivolumabNeoplasm StagingAxitinibAntibodies, Monoclonal, Humanized

Stichwörter der Autor:innen

Renal cell carcinomacombination drug therapyimmune checkpoint inhibitorsurvival ratetyrosine kinase inhibitor

Substanzen

Immune Checkpoint InhibitorsProtein Kinase InhibitorsNivolumabAxitinibAntibodies, Monoclonal, Humanized

Autor:innen und Institutionen

  • Department of Urology and Renal Transplantation, Nagasaki University Hospital, Nagasaki, Japan.
  • Department of Urology and Renal Transplantation, Nagasaki University Hospital, Nagasaki, Japan ohba-k@nagasaki-u.ac.jp.

Zitieren

APA

Mukae, Y., Ohba, K., Nakanishi, H., Oki, M., Kawada, K., Matsuda, T., Mitsunari, K., Matsuo, T., Mochizuki, Y., & Imamura, R. (2026). Comparative Analysis of Immune-based Combination Therapy as First-line Treatment for Advanced Renal Cell Carcinoma. In Vivo. https://doi.org/10.21873/invivo.14203

Vancouver

Mukae Y, Ohba K, Nakanishi H, Oki M, Kawada K, Matsuda T, et al. Comparative Analysis of Immune-based Combination Therapy as First-line Treatment for Advanced Renal Cell Carcinoma. In Vivo. 2026. doi:10.21873/invivo.14203

BibTeX
@article{Mukae2026,
  author = {Mukae, Yuta and Ohba, Kojiro and Nakanishi, Hiromi and Oki, Masaharu and Kawada, Ken and Matsuda, Tsuyoshi and Mitsunari, Kensuke and Matsuo, Tomohiro and Mochizuki, Yasushi and Imamura, Ryoichi},
  title = {Comparative Analysis of Immune-based Combination Therapy as First-line Treatment for Advanced Renal Cell Carcinoma},
  journal = {In Vivo},
  year = {2026},
  doi = {10.21873/invivo.14203}
}
Kostenlos starten →